Abstract: Provided is a catalyst layer for fuel cell having improved heat-dissipating performance and durability. The catalyst layer for fuel cell according to the present invention is a catalyst layer for fuel cell comprising a first composite and a second composite, wherein the first composite includes: a supporting material, a catalyst including metal particles supported on the supporting material, and a first ionomer coated on the surface of the catalyst; the second composite includes a heat-dissipating material and a second ionomer, the second ionomer is not coated on the surface of the catalyst, and the first ionomer and the second ionomer are identical with or different from each other.

Abstract: Provided is a method for manufacturing a polarizing plate, comprising a step of irradiating an optical laminate with ultraviolet rays having an emission wavelength band of 380 nm to 410 nm. The optical laminate sequentially comprises a first base film, a first adhesive layer, a linear polarizer, a second adhesive layer, a second base film and a reverse dispersion liquid crystal layer. The first adhesive layer and the second adhesive layer each comprise a photosensitizer for initiating a curing reaction in a wavelength band of 350 nm to 410 nm, and the ultraviolet rays are irradiated on the first base film side of the optical laminate.

Abstract: Provided is an optical system which may acquire a hyperspectral image by acquiring a spectral image of an object to be measured, which includes, to collect spectral data and train the neural network, an image forming part forming an image from an object to be measured and transmitting collimated light, a slit moving to scan the incident image and passing and outputting a part of the formed image, and a first optical part obtaining spectral data by splitting light of the image received through the slit by wavelength. Also, the system includes, to decompose overlapped spectral data and to infer hyperspectral image data through the trained neural network, an image forming part forming an image from an object to be measured and transmitting collimated light, and a first optical part obtaining spectral data by splitting light of the received image by wavelength.

Abstract: The present disclosure relates to the preparation of citrullinated vimentin antigen-specific immune tolerogenic dendritic cells and a composition for preventing or treating heart failure after myocardial infarction comprising the same. According to the present disclosure, it is confirmed that immune tolerogenic dendritic cells differentiated by treating immature dendritic cells with citrullinated vimentin regulate the expression of immune-related factors and have an excellent therapeutic effect on heart failure caused by myocardial infarction.

Abstract: A vehicular air conditioning system includes a compressor configured to compress a gaseous refrigerant to have a high temperature and a high pressure while an output rotation speed thereof is variably controlled according to a cooling load in a vehicle interior, and a compressor performance deterioration determination part configured to determine whether or not the performance of the compressor has deteriorated according to the magnitude of a difference between an amount of work (W) of the compressor and an amount of power consumption (kW) of the compressor.

Abstract: A vehicle seat reinforcement device includes a leg portion mounted on a floor panel, a seat cushion frame slidably mounted on the leg portion, and a load reinforcing structure connected between the leg portion and the seat cushion frame, wherein when a seat belt anchorage load is transferred to the seat cushion frame, the seat cushion frame is locked to the leg portion by the load reinforcing structure.

Abstract: Provided is a duct docking device for a ventilation seat of a vehicle. The duct docking device enables air to be easily blown to a seatback and a seat cushion with a passenger in a seat using only one blower by enabling a seatback duct mounted at the seatback and a seat cushion duct mounted at the seat cushion to be hermetically docked through a connector duct, etc. at an unfolded position of the seatback in which a passenger can sit, and by enabling the seatback duct mounted at the seatback and the seat cushion duct mounted at the seat cushion to be separated from each other at a folded position of the seatback in consideration of that there is no passenger in the seat.

Abstract: Provided is a composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs, and more particularly, a pharmaceutical composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs and Moutan root bark, a health functional food composition of feed composition for preventing or alleviating obesity including the composition, and a method of preventing or treating obesity including administering the pharmaceutical composition to an individual having obesity or a risk of developing obesity. The mixed extract of Cinnamomi twigs and Moutan root bark may inhibit fat absorption in the intestinal tract and increases in body weight causing obesity by single-dose administration, reduce lipid content in the blood, decrease weight and size of adipocytes, effectively inhibit accumulation of fat in liver tissue, and inhibit diarrhea, a serious side effect of Xenical™, by long-term administration.

Abstract: The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabetic

Abstract: Provided is a composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs, and more particularly, a pharmaceutical composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs and Moutan root bark, a health functional food composition of feed composition for preventing or alleviating obesity including the composition, and a method of preventing or treating obesity including administering the pharmaceutical composition to an individual having obesity or a risk of developing obesity. The mixed extract of Cinnamomi twigs and Moutan root bark may inhibit fat absorption in the intestinal tract and increases in body weight causing obesity by single-dose administration, reduce lipid content in the blood, decrease weight and size of adipocytes, effectively inhibit accumulation of fat in liver tissue, and inhibit diarrhea, a serious side effect of Xenical™, by long-term administration.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.

Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema containing a mixed extract of Hedera helix leaves and Coptis chinensis as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema further containing an extract of Rheum palmatum, Puerariae radix, Ginkgo leaves, Cassiae semen, blueberry, bilberry, raspberry, or grape seeds as an active ingredient, in addition to the mixed extract of Hedera helix leaves and Coptis chinensis.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.

Abstract: The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabetic

Abstract: The present invention relates to the obesity-curative or obesity-preventive effect of a Polygonum cuspidatum butanol fraction and a Polygonum cuspidatum ethylacetate fraction, and more particularly, to a pharmaceutical composition and a functional food for treating obesity, the pharmaceutical composition and the functional food comprising a Polygonum cuspidatum butanol fraction (POCU-1b) and an ethylacetate fraction as active ingredients, wherein the Polygonum cuspidatum butanol fraction and the ethylacetate fraction inhibit effectively the activity of pancreatic lipase, an important enzyme involving in fat absorption in a living body, and have excellent inhibitory effect on fat absorption in the short term fat absorption-inhibitory animal experiments using lipid emulsions.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetic complications comprising the extract of Homonoia riparia Lour. or the fraction thereof as an active ingredient. More particularly, the extract of Homonoia riparia Lour. or the fractions thereof of the present invention can inhibit the activity of aldose reductase and the generation of the advanced glycation endproducts, the index of diabetic complications, and have powerful activity of inhibiting diabetic complications with brining the anti-cataract, anti-retinopathy, and anti-neuropathy effect, and have the activity of anti-oxidation as well, so that they can be effectively used as an active ingredient of a pharmaceutical composition for the prevention and treatment of diabetic complications.

Abstract: Provided is a hollow-fiber membrane module comprising a submodule inside which raw water is circulated and water treatment is carried out, and a piping unit which is connected to the submodule and through which the raw water and air and treated water flow, such that flow rates can be increased and energy consumption can be minimized through the circulation of a fluid.

Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema containing a mixed extract of Hedera helix leaves and Coptis chinensis as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema further containing an extract of Rheum palmatum, Puerariae radix, Ginkgo leaves, Cassiae semen, blueberry, bilberry, raspberry, or grape seeds as an active ingredient, in addition to the mixed extract of Hedera helix leaves and Coptis chinensis.

Abstract: The present invention provides a novel biphenyl compound or pharmaceutically acceptable salts thereof, methods for preparing the same, and pharmaceutical compositions for preventing or treating diabetic complications containing the same as an active ingredient. Novel biphenyl compounds, according to the present invention, effectively suppress generation activity of advanced glycation end products, which cause diabetic complications and are a criterion for evaluating the effectiveness of a treating agent for diabetic complications, and show an excellent therapeutic effect on retina blood vessels, increased occludin, and decreased angiogenic growth factor in actual diabetic retinopathy induced retina. Thus, novel biphenyl compounds according to the present invention can be used effectively as an active ingredient in compositions for preventing or treating diabetic complications such as diabetic retinopathy.

Abstract: The present invention relates to a treatment agent for diabetic complications, and a method for the treatment of diabetic complications using the same. The present invention confirmed that Osteomeles schwerinae extract and its fractions inhibited the generation of AGEs, the index for diabetic complications, inhibited the activation of aldose reductase, had anti-cataract activity, and had anti-oxidative activity. Thus, the present invention relates to a preventive and therapeutic agent for diabetic complications containing the said Osteomeles schwerinae extract and its fraction as an active ingredient.